The New Default. Your hub for building smart, fast, and sustainable AI software
Table of Contents
Executive summary
Whether a digital health product counts as a medical device comes down to its intended use and risk profile: how you market, label, and distribute it.
Products that diagnose disease, guide treatment, or directly influence a clinical decision almost always need regulatory approval.
Products that promote general wellness without medical claims usually do not.
That one distinction sets your development cost, your time to market, and the claims you can legally make.
Digital health is now a large, fast-growing market. One analysis puts the global digital health market at $377 billion in 2024, and another estimates $947 billion by 2030. New products launch every week, and their creators all hit the same question:
When does a digital health product become a medical device?
The answer shapes everything from development costs to regulatory timelines, and recent enforcement has made the classification harder to ignore.
Types of Digital Health Products
Wearables range from basic fitness trackers like Fitbit, built for step counting and general wellness, to regulatory-approved medical-grade monitors.
Mobile health apps cover wellness apps like Headspace that avoid medical claims, patient-engagement platforms for scheduling and communication, and prescription digital therapeutics like reSET for substance use disorder, which need full FDA authorization backed by clinical trials.
Telemedicine platforms include basic video tools for remote consultations, AI-powered diagnostic software that needs medical device clearance, and clinical decision support systems that read patient data to suggest diagnoses.
Remote monitoring devices span consumer wellness trackers and medical-grade systems. Continuous glucose monitors like Dexcom need regulatory approval; general activity monitors stay consumer products. What separates them is whether the device produces clinical-grade data for medical decisions or general insights for personal use.
AI diagnostic tools are the fastest-growing regulated category. They run from imaging systems that read mammograms and chest X-rays to decision-support tools that recommend treatment. Most target radiology today, though pathology, cardiology, and primary care are catching up.
Digital health products all use technology to improve people's health, but the category is broad enough that the label alone tells you very little.
At one end sit fitness trackers and wellness apps that help you keep a healthy routine. At the other sit AI diagnostic tools, digital therapeutics, wearables that call emergency services during a cardiac event, and surgical robots like the da Vinci Surgical System. Same sector, very different stakes.
A smartwatch that counts steps is different from software that reads medical images for signs of cancer. Both improve health outcomes; only one needs FDA approval as a medical device.
The line moves, too. Sleep apnea detection on the Apple Watch and the same feature on the Samsung Galaxy Watch earned FDA clearance, which turned consumer gadgets into regulated diagnostic tools. More consumer devices keep adding clinical features, and each one redraws where the regulatory line falls.
What Makes a Medical Device?
Whether a product counts as "medical" is a legal question, and the answer changes with every jurisdiction you sell into.
The core definitions are consistent worldwide, even as enforcement tightens. Classification comes down to two things: intended use and risk.
The EU defines a medical device as any instrument, apparatus, software, or material "intended by the manufacturer to be used for human beings" for purposes including "diagnosis, prevention, monitoring, treatment or alleviation of disease." The U.S. FDA uses similar language under the Federal Food, Drug, and Cosmetic Act.
The key word is "intended." Regulators look at how you market, label, and distribute your product to determine intended use. A heart rate monitor positioned for fitness carries different requirements than one marketed to detect arrhythmias.
Enforcement is catching up to that idea. The 2025 WHOOP warning letter over blood pressure monitoring is a good example: the FDA said blood pressure monitoring is "inherently associated" with medical diagnosis, regardless of any wellness disclaimer.
United States: the FDA's three-tier system
In the United States, the FDA's three-tier classification system sets requirements by risk and intended use. Class I devices like basic electronic thermometers need only general controls. Class II devices, which cover most digital health apps, need 510(k) clearance showing substantial equivalence to a product already on the market. Class III devices for life-critical uses need full premarket approval with clinical trials.
The intended use doctrine does most of the work here. It looks at what you say your product is for, as reflected in labeling, marketing, and instructions. Make a diagnostic claim, recommend a treatment, or support a clinical decision, and you are almost certainly looking at a medical device, whatever the underlying technology.
European Union: Rule 11 and SaMD
In the European Union, the Medical Device Regulation uses four classes (I, IIa, IIb, III), and Rule 11 governs software specifically. Most digital health software lands in Class IIa or higher, which means a notified body has to be involved and the product carries CE marking. Only narrow cases, such as basic medical calculators, qualify as Class I with self-certification.
Software as a Medical Device (SaMD) frameworks, adopted internationally, sort products by how critical the healthcare situation is and how the information is used: to treat or diagnose, to drive clinical management, or to inform it. For a fuller breakdown, read What Are the Global SaMD Standards: Regulations for Medical Software.
Key Differences: Medical Devices vs Consumer Products
The split comes down to risk and medical purpose.
Medical devices target a specific medical problem: detecting disease, guiding treatment, or delivering therapy.
Wellness apps promote general fitness and lifestyle habits.
Building a medical device costs a lot more. You need clinical trials, regulatory submissions, quality management systems, and ongoing compliance monitoring. The process is slow, but it proves your product is safe and works.
Non-medical health and wellness products launch faster and cheaper, but they are limited in what they can claim. They have to avoid specific medical claims and lean on careful language like "may help reduce the risk of" certain chronic conditions or "supports general wellness." They cannot talk about diagnosing, treating, curing, or preventing disease, with few exceptions.
The same limits apply to design. Consumer products cannot deliver real-time medical alerts, specific medical recommendations, or clinical decision support. They have to present information for the user to interpret, not direct a medical intervention.
Medical Device vs Consumer Wellness Product
Medical device | Consumer wellness product | |
|---|---|---|
Primary purpose | Diagnose, treat, or guide a clinical decision | General fitness and lifestyle improvement |
Claims allowed | "Detects," "diagnoses," "treats," "monitors [condition]" | "Supports wellness," "may help reduce the risk of..." |
US path | 510(k) clearance (Class II) or PMA (Class III) | No FDA submission when there are no medical claims |
EU path | Notified body review and CE marking (usually Class IIa or higher) | Self-certification when outside MDR scope |
Clinical evidence | Required (trials, validation) | Not required |
Time and cost | Higher: months to years, plus QMS and ongoing compliance | Lower: faster launch, lighter overhead |
Reimbursement | Possible through payers and health systems | Rare; usually direct-to-consumer |
Example | Headspace, basic Fitbit trackers |
Why Pursue Medical Device Classification?
Our clients who choose the medical device path tend to report the same benefits:
It sets you apart. The wearables market is crowded, and plenty of devices barely work. "Trust us, ours works" is a weak pitch; clearance is proof.
It forces real evidence. Certification requires clinical trials, so you actually measure how well your device performs. That takes time, but it usually makes the product better.
It earns credibility. A cleared device reads as more reliable and professional than an uncertified one.
It supports a higher price, and a higher margin.
The regulated market also has fewer "me-too" products that don't deliver, so clearance helps you stand out for the right reasons. Clinical trials back up what you say with data instead of marketing promises.
On the business side, medical devices command higher prices and stronger reimbursement potential. Health systems and providers take regulated products more seriously than wellness apps, and the trust that comes with FDA clearance or CE marking opens doors that stay shut for unregulated products.
Should You Build a Medical Device?
Both certified medical devices and consumer products can improve people's lives. What matters is whether you solve a real problem well, not the regulatory label by itself.
The choice depends on your product's intended use, target market, and business model. Medical devices bring credibility and reimbursement potential, but they cost you in clinical validation and regulatory compliance.
The question to answer first: does your product diagnose, treat, or directly influence a medical decision? If yes, plan for medical device requirements. If your focus is general wellness and lifestyle, you have more room to move. And if you are stuck at the crossroads, reach out and we'll help you figure it out.
Key Takeaways
Intended use decides classification. How you market, label, and distribute a product matters more than the technology inside it.
Medical claims trigger regulation. Words like diagnose, treat, and monitor a condition push you into medical device territory; "supports wellness" generally does not.
Jurisdiction changes the path. The US uses a three-tier system with 510(k) or PMA; the EU uses MDR, with Rule 11 for software and CE marking.
Enforcement is tightening. The WHOOP blood pressure warning letter shows the FDA will look past wellness disclaimers when a feature is tied to diagnosis.
The tradeoff is cost versus credibility. The medical path is slower and more expensive, but it unlocks clinical proof, higher prices, and reimbursement.
FAQ
)




